title: Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.
abstract: There are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for hormone-naïve prostate cancer. Through a protocol amendment, this will be assessed in the STAMPEDE trial, with overall survival as primary outcome measure.
authors.affiliation: The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London and Sutton, UK.
authors.forename: Gerhardt
authors.initials: G
authors.lastname: Attard
authors.affiliation: Medical Research Council Clinical Trials Unit at University College London, London, UK. Electronic address: m.sydes@ucl.ac.uk.
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Sydes
authors.affiliation: Cardiff University School of Medicine, Velindre Hospital, Cardiff, UK.
authors.forename: Malcolm D
authors.initials: MD
authors.lastname: Mason
authors.affiliation: Department of Urology, The Christie NHS Foundation Trust, Manchester, UK.
authors.forename: Noel W
authors.initials: NW
authors.lastname: Clarke
authors.affiliation: University of Bern, Bern, Switzerland.
authors.forename: Daniel
authors.initials: D
authors.lastname: Aebersold
authors.affiliation: The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London and Sutton, UK.
authors.forename: Johann S
authors.initials: JS
authors.lastname: de Bono
authors.affiliation: The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London and Sutton, UK.
authors.forename: David P
authors.initials: DP
authors.lastname: Dearnaley
authors.affiliation: The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London and Sutton, UK.
authors.forename: Chris C
authors.initials: CC
authors.lastname: Parker
authors.affiliation: Medical Research Council Clinical Trials Unit at University College London, London, UK.
authors.forename: Alastair W S
authors.initials: AW
authors.lastname: Ritchie
authors.affiliation: Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
authors.forename: J Martin
authors.initials: JM
authors.lastname: Russell
authors.affiliation: Department of Urology, University Hospital, Bern, Switzerland.
authors.forename: George
authors.initials: G
authors.lastname: Thalmann
authors.affiliation: Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.
authors.forename: Estelle
authors.initials: E
authors.lastname: Cassoly
authors.affiliation: Patient representative, Stockton-on-Tees, UK.
authors.forename: Robin
authors.initials: R
authors.lastname: Millman
authors.affiliation: Patient representative, Northampton, UK.
authors.forename: David
authors.initials: D
authors.lastname: Matheson
authors.affiliation: Medical Research Council Clinical Trials Unit at University College London, London, UK.
authors.forename: Francesca
authors.initials: F
authors.lastname: Schiavone
authors.affiliation: Medical Research Council Clinical Trials Unit at University College London, London, UK.
authors.forename: Melissa R
authors.initials: MR
authors.lastname: Spears
authors.affiliation: Medical Research Council Clinical Trials Unit at University College London, London, UK.
authors.forename: Mahesh K B
authors.initials: MK
authors.lastname: Parmar
authors.affiliation: University of Warwick, Warwick, UK.
authors.forename: Nicholas D
authors.initials: ND
authors.lastname: James
mesh_terms: D006801:Humans; D008297:Male; D000726:Androgen Antagonists / Q000008:administration & dosage; D000736:Androstenes / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001549:Benzamides; D065607:Cytochrome P-450 Enzyme Inhibitors / Q000008:administration & dosage; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000008:administration & dosage / Q000031:analogs & derivatives; D011241:Prednisone / Q000008:administration & dosage; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D012107:Research Design; D013254:Steroid 17-alpha-Hydroxylase / Q000037:antagonists & inhibitors / Q000378:metabolism; D013557:Switzerland; D016896:Treatment Outcome; D006113:United Kingdom; D016032:Randomized Controlled Trials as Topic; D015337:Multicenter Studies as Topic
chemical_list: C089740:abiraterone; D000726:Androgen Antagonists; D000736:Androstenes; D001549:Benzamides; C501892:CYP17A1 protein, human; D065607:Cytochrome P-450 Enzyme Inhibitors; C540278:enzalutamide; D009570:Nitriles; D010669:Phenylthiohydantoin; D011241:Prednisone; D013254:Steroid 17-alpha-Hydroxylase